Oct-09-24 10:15AM
|
|
Oct-03-24 09:00PM
|
|
Sep-30-24 05:17PM
|
|
Sep-23-24 09:30AM
|
|
Sep-20-24 11:30AM
|
|
11:01AM |
Loading… |
11:01AM
|
|
09:47AM
|
|
06:11AM
|
|
Sep-18-24 04:20PM
|
|
Sep-12-24 08:44AM
|
|
Sep-10-24 05:00PM
|
|
Sep-09-24 03:57PM
|
|
08:00AM
|
|
Sep-02-24 07:33AM
|
|
Aug-31-24 01:04AM
|
|
09:34AM |
Loading… |
Aug-28-24 09:34AM
|
|
Aug-26-24 09:15AM
|
|
Aug-23-24 03:00PM
|
|
Aug-22-24 12:50PM
|
|
09:51AM
|
(Thomson Reuters StreetEvents) |
Aug-21-24 09:28PM
|
|
08:53PM
|
|
06:00PM
|
|
05:15PM
|
|
04:13PM
|
(Associated Press Finance) |
04:05PM
|
|
Aug-20-24 10:29AM
|
|
09:01AM
|
|
Aug-19-24 10:18AM
|
|
Aug-18-24 02:00PM
|
|
09:15AM |
Loading… |
Aug-16-24 09:15AM
|
|
Aug-15-24 08:00AM
|
|
Aug-14-24 10:00AM
|
|
Aug-12-24 12:58PM
|
|
Aug-02-24 08:00AM
|
|
Jul-31-24 07:25PM
|
|
Jul-30-24 01:01PM
|
|
Jul-29-24 09:55AM
|
|
Jul-26-24 03:35PM
|
|
Jul-25-24 04:09PM
|
|
Jul-24-24 07:24AM
|
|
Jul-23-24 06:33AM
|
(Pharmaceutical Technology) |
Jul-22-24 11:19AM
|
|
10:47AM
|
|
09:01AM
|
|
Jul-21-24 09:12PM
|
|
Jul-19-24 08:46AM
|
|
Jul-16-24 04:01PM
|
|
Jul-13-24 12:05PM
|
|
Jul-01-24 01:04PM
|
|
09:01AM
|
|
Jun-28-24 11:30AM
|
|
Jun-27-24 12:06PM
|
|
09:48AM
|
|
Jun-26-24 10:07AM
|
|
Jun-21-24 03:10AM
|
|
Jun-14-24 06:54AM
|
|
Jun-06-24 12:01PM
|
|
Jun-03-24 11:27AM
|
|
11:00AM
|
|
May-31-24 07:34PM
|
|
May-30-24 04:24PM
|
|
02:36PM
|
|
12:15PM
|
(Associated Press Finance) |
11:58AM
|
|
11:34AM
|
|
07:47AM
|
|
07:39AM
|
|
07:34AM
|
|
06:38AM
|
(Thomson Reuters StreetEvents) |
May-29-24 08:53PM
|
|
06:00PM
|
|
05:15PM
|
|
04:14PM
|
(Associated Press Finance) |
04:05PM
|
|
May-28-24 11:44AM
|
|
May-26-24 07:00AM
|
|
May-23-24 04:05PM
|
|
09:15AM
|
|
08:04AM
|
|
May-22-24 04:05PM
|
|
10:00AM
|
|
08:00AM
|
|
May-17-24 02:30PM
|
|
May-16-24 10:59AM
|
|
08:00AM
|
|
May-13-24 09:30AM
|
|
May-02-24 04:53PM
|
|
12:10PM
|
|
11:45AM
|
|
09:30AM
|
|
May-01-24 10:31AM
|
|
08:45AM
|
|
08:00AM
|
|
Apr-29-24 08:45AM
|
|
Apr-18-24 04:30PM
|
|
Apr-16-24 08:00AM
|
|
Apr-15-24 08:00AM
|
|
Apr-09-24 11:37PM
|
|
12:02PM
|
|
|
|
|
Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
MCDONNELL PADRAIG | President and CEO | Sep 27 '24 | Sale | 150.00 | 47 | 7,050 | 24,071 | Sep 30 01:08 PM | Grau Dominique | Senior Vice President | Sep 26 '24 | Sale | 145.00 | 9,990 | 1,448,550 | 40,011 | Sep 27 05:02 PM | Grau Dominique | Senior Vice President | Sep 26 '24 | Sale | 145.00 | 5,010 | 726,450 | 46,762 | Sep 27 05:02 PM | MCDONNELL PADRAIG | Officer | Sep 27 '24 | Proposed Sale | 150.00 | 47 | 7,050 | | Sep 27 12:19 PM | Grau Dominique | Officer | Sep 26 '24 | Proposed Sale | 145.00 | 15,000 | 2,175,000 | | Sep 26 02:52 PM | MCDONNELL PADRAIG | President and CEO | Aug 22 '24 | Sale | 145.00 | 1,958 | 283,910 | 24,118 | Aug 23 11:43 AM | MCDONNELL PADRAIG | Officer | Aug 22 '24 | Proposed Sale | 145.00 | 1,958 | 283,910 | | Aug 22 12:39 PM | MCDONNELL PADRAIG | President and CEO | Jul 26 '24 | Sale | 140.00 | 1,958 | 274,120 | 26,076 | Jul 30 10:42 AM | MCDONNELL PADRAIG | Officer | Jul 26 '24 | Proposed Sale | 140.00 | 1,958 | 274,120 | | Jul 26 10:56 AM | MCDONNELL PADRAIG | President and CEO | Jun 18 '24 | Sale | 135.00 | 1,958 | 264,330 | 28,034 | Jun 20 06:54 PM | Grau Dominique | Senior Vice President | Jun 10 '24 | Sale | 133.28 | 15,000 | 1,999,262 | 49,486 | Jun 12 10:40 AM | MCDONNELL PADRAIG | President and CEO | Jun 03 '24 | Sale | 130.00 | 1,958 | 254,540 | 25,185 | Jun 05 10:08 AM | Binns Philip | Senior Vice President | Mar 25 '24 | Sale | 147.54 | 2,827 | 417,096 | 9,997 | Mar 27 01:29 PM | McMullen Michael R. | CEO and President | Mar 08 '24 | Sale | 150.00 | 52,297 | 7,844,550 | 253,909 | Mar 12 02:37 PM | Gonsalves Rodney | V.P., Corporate Controller | Mar 07 '24 | Sale | 149.00 | 4,828 | 719,348 | 21,329 | Mar 08 12:05 PM | FIELDS HEIDI | Director | Mar 05 '24 | Sale | 144.34 | 1,658 | 239,316 | 54,976 | Mar 07 10:38 AM | Binns Philip | Senior Vice President | Dec 27 '23 | Sale | 139.78 | 2,880 | 402,566 | 12,824 | Dec 28 01:46 PM | Gonsalves Rodney | V.P., Corporate Controller | Dec 18 '23 | Sale | 137.69 | 1,500 | 206,538 | 26,133 | Dec 19 02:34 PM | Ancher-Jensen Henrik | Sr Vice President | Dec 15 '23 | Option Exercise | 111.36 | 11,703 | 1,303,235 | 108,835 | Dec 19 02:33 PM | Ancher-Jensen Henrik | Sr Vice President | Dec 15 '23 | Sale | 138.36 | 26,331 | 3,643,157 | 82,504 | Dec 19 02:33 PM | McMullen Michael R. | CEO and President | Dec 13 '23 | Option Exercise | 42.12 | 2,751 | 115,872 | 308,957 | Dec 15 05:08 PM | McMullen Michael R. | CEO and President | Dec 13 '23 | Sale | 130.00 | 2,751 | 357,630 | 306,206 | Dec 15 05:08 PM | McMullen Michael R. | CEO and President | Dec 07 '23 | Option Exercise | 42.12 | 62,467 | 2,631,110 | 368,673 | Dec 08 02:59 PM | McMullen Michael R. | CEO and President | Dec 07 '23 | Sale | 130.00 | 62,467 | 8,120,710 | 306,206 | Dec 08 02:59 PM |
|